Category: Brisbane

Arch Oncology adds $105M for better way to get immune cells to gobble up tumors

Arch Oncology, BioPharma, biopharma nl, Brisbane, California, cancer drugs, Daily, Immunotherapy, investing, Pharma, SYN, Top Story / April 27, 2021 April 27, 2021

Several companies are developing immunotherapies targeting the “don’t eat me” cancer protein CD47. Arch Oncology, which is developing drugs with features that could set them apart from the field, now has $105 million for multiple clinical trials.

Takeda to buy out Maverick in $525M bet on bringing T cells to solid tumors

Acquisitions, BioPharma, biopharma nl, Brisbane, California, cancer immunotherapy, Daily, Maverick Therapeutics, Pharma, SYN, Takeda Pharmaceutical, Top Story / March 9, 2021 March 9, 2021

Takeda Pharmaceutical and Maverick Therapeutics have been R&D partners since 2017. In buying out its partner, Takeda acquires technology and drug candidates that could offer advantages compared to CAR-T therapies, including the potential to treat solid tumors.

Ellume gets $232M contract for at-home Covid-19 tests

at-home testing, Brisbane, COVID-19, Diagnostics, ellume, Policy, SYN, Top Story / February 2, 2021 February 2, 2021

Ellume, whose at-home Covid-19 test was cleared by the FDA in December, got a $232 million contract from the Department of Health and Human Services to deliver 8.5 million tests.